Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calypte seeks to expand HIV-1 urine test sales in China:

This article was originally published in Clinica

Executive Summary

Calypte Biomedical is making progress with efforts to broaden the market for its HIV-1 urine test in China. The firm has submitted data from trials of the EIA-based test to the Chinese State Drug Administration (SDA) for approval by its biologics branch. The test is already approved in China via the medical devices branch of the SDA, but approval by the biologics branch makes it "more marketable to certain government testing institutions", says the Alameda, California firm. The latest trials generated urine HIV data on over 10,000 Chinese subjects. They estimated the sensitivity of the test at 100% and its specificity at 99.95%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063904

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel